Yes, we have probably patched things up with the FDA. Yes, we have CA and Dr JL on board along with a CFO who think differently than the leadership of the past. We settled with Amarex who screwed us over royally no matter what anyone says about why the $ amount was what it was. One cannot fully appreciate what it means being a small biotech company with an approval and producing revenue vs where we are today. Further it is hard to appreciate the added damage this has caused having to sell hundreds of millions of shares to stay afloat much less more shares to move forward.

It is abundantly clear CYDY is probably not going to get the benefit of the doubt trading wise, assuming the news flow remains positive but without a large federal grant or BP partner news. The overhang of a large volume of OS is a significant challenge to overcome and it may worsen still. News like yesterday's could have easily resulted in ten's of millions of shares trading and a double or triple in PPS. Perhaps it will happen in the coming days as the current private placement closes.

We need to get off the OTC and stop relying on Fife and Paulson(no offense Paulson investors, I appreciate your financial backing).

I am thankful for what the team has managed so far but we are not seeing any investment jingle in our pockets. Rebranding, whatever that entails, needs to happen to get new investors/partners attention. Now that much has been corrected corporate wise and before clinical results come in is the time to make a splash